Diagnostic and Therapeutic Developments across Global Healthcare

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This Genetic Technology TOE depicts recent diagnostic and therapeutic advances across the global healthcare industry. Clinical trial scenario for monoclonal antibody therapies for migraine are also depicted.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & We

Table of Contents

Diagnostic and Therapeutic Developments across Global HealthcareRecent Diagnostic and Therapeutic AdvancesAdvancing Epigenetic and Molecular Diagnostics across Urologic and Lung CancersExpanded Collaboration for Novel Migraine Antibody Platform3D Scaffold Platform for Organ TransplantsMobile App for Diabetes ManagementClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.